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ABSTRACT 
The aim of this case report was to describe a miscarriage which occurred 6 days after an intravitreal Ranibizumab 
(IVR) injection. A 24-year-old female patient with type 1 diabetes diagnosed with diabetic macular edema in her 
left eye planned for 3 injections of IVR at one-month intervals. She had been receiving insulin injections 3 times a 
day and her Hemoglobin A1C (HbA1c) was in the approximate range of 6–7%. An ophthalmologic examination 
revealed that the patient’s Snellen corrected distance visual acuity (CDVA) was 10/10 in her right eye and 3/10 in 
her left eye. The patient was unaware of her pregnancy at the time of initial injection. Two days after the first 
injection, she found out that she was 5 weeks pregnant. This was the first pregnancy for the patient and there 
were no risk factors for miscarriage rather than diabetes. Six days after the injection, she was admitted to the 
hospital due to severe abdominal pain and vaginal bleeding. Miscarriage was diagnosed and she underwent 
curettage procedure. We concluded that pregnancy tests should be administered prior to intravitreal injection for 
female patients of reproductive age, and patient testimony should not be the sole reason to dismiss the possibility 
of pregnancy. 
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INTRODUCTION
Intravitreal Anti-vascular endothelial growth factor (Anti-
VEGF) agents (IVAs) are frequently used to treat age-
related macular degeneration, diabetic retinopathy and 
retinal vein branch occlusion. Although IVAs are usually 
used to treat middle-aged and elderly patients, they can 
be used to treat patients with type 1 diabetes and 
diabetic macular edema, idiopathic choroid 
neovascularization and retinal vein branch occlusion 
sometimes at young ages [1-3].  
The United States Food and Drug Administration (FDA) 
classifies Ranibizumab, Bevacizumab and Aflibercept as 
category C for use during pregnancy, indicating that 
these drugs have been shown to be toxic to the embryo 
and fetus in animal studies but evidence in humans is 
insufficient to draw a conclusion [2]. While the most 
common systemic side effects of IVAs are hypertension, 
proteinuria and cerebrovascular attack, they could cause 
preeclampsia in pregnant patients, lowered weight gain 
in mothers and fetuses, teratogenic effects on embryos 
and even miscarriage [3-6].  
While it is standard practice to obtain patient history 
related to cardiovascular health for as long as 6 months 
before any IVA injection, the necessity of assessing the 
possibility of pregnancy in female patients of 
reproductive age should not be overlooked. However, 
instead of relying on patient knowledge, a medical 
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pregnancy test is required to rule out pregnancy. If IVA 
treatment is deemed necessary, the patient should be 
warned about the potential risks involved, and, if 
possible, treatment should be postponed until the first 
trimester. This case report describes a case of 
miscarriage which occurred 6 days after an intravitreal 
Ranibizumab (IVR) injection and underlines the 
importance of good history taking regarding pregnancy. 
However, pregnancy tests should be performed prior to 
intravitreal injection for female patients of reproductive 
age. 
CASE REPORT 
The case provided a written, informed consent for the 
publication of this report. The patient was a 24-year-old 
female with type 1 diabetes diagnosed at the age of 8. 
She had been receiving insulin injections 3 times a day, 
and her Hemoglobin A1C (HbA1c) was in the 
approximate range of 6–7%. Her last measured HbA1c 
was 6.4% in the first examination time.  She was 
consulted to ophthalmology clinic of Fatih Sultan 
Mehmet Training and Research Hospital, Istanbul, Turkey 
from endocrinology clinic in August 2018. An 
ophthalmologic examination revealed that the patient’s 
Snellen corrected distance visual acuity (CDVA) was 
10/10 in her right eye and 3/10 in the left eye. 
Intraocular pressure levels were 12 millimeter of mercury 
(mmHg) in the right eye and 14 mmHg in the left eye. 
There were no other complications related to diabetes 
except for those related to her vision, and her 
biomicroscopic examination results were normal. A 
fundus examination revealed diabetic macular edema in 
the left eye and no noteworthy results in the right eye. 
Ocular coherence tomography (OCT) further revealed a 
cystoid macular edema (CME) around the fovea and an 
increase in macular thickness in the left eye and normal 
macular anatomy and thickness in the right eye (Fig. 1). 
The patient was recommended 3 IVR injections at one-
month intervals to treat the diabetic macular edema in 
her left eye. In her pre-injection inquiry, the patient 
stated that she had been married for 6 months and she 
was not pregnant. She received 0.05mL/0.5mg IVR in her 
left eye under sterile condition. During check-up one 
month later, CME was decreased in her left eye (Fig. 2) 
but the patient informed us that she had experienced a 
miscarriage six days after the first injection. She also 
stated that her period had been late but she was not 
aware of her pregnancy at the time of intervention. She 
stated that she had a positive result from a pregnancy 
test taken two days after the injection. She confirmed 
the result by visiting an obstetrician and discovered that 
she was 5 weeks pregnant. This was her first pregnancy 
and there were no risk factors for miscarriage rather than 
her diabetes. She had no history of any previous 
miscarriage, ectopic pregnancy, pelvic surgery or 
infection. She did not have any related family history and 
her blood pressure was within the normal range 
(110/65mmhg) and she had no dyslipidemia. She was 
admitted to emergency service with severe abdominal 
pain and vaginal bleeding 6 days after the IVR injection. 
Miscarriage was diagnosed and a curettage procedure 
was performed by the obstetrician in charge. 
 
 
 
 
Figure 1: Ocular Coherence Tomography (OCT) Findings Before Intravitreal Ranibizumab Injection Revealed a Cystoid Macular Edema (CME) Around the 
Fovea and an Increase in Macular Thickness in the Left Eye (Right Figure) and Normal Macular Anatomy and Thickness in the Right Eye (Left Figure). 
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Figure 2: Ocular Coherence Tomography (OCT) Findings One Month After Single Intravitreal Ranibizumab Injection Revealed Decreased Cystoid Macular 
Edema in the Left Eye (Right Figure) and Normal Macular Anatomy and Thickness in the Right Eye (Left Figure). 
DISCUSSION
Intravitreal Ranibizumab may cause miscarriage, 
especially at first trimester. For this reason, we should 
not rely on a patient history and must take pregnancy 
test. The ophthalmologist should be careful before 
intravitreal injection if the patient is female and in the 
reproductive age.  
Vascular endothelial growth factors (VEGFs) promote 
vasculogenesis, neoangiogenesis and vascular 
permeability. Human and animal studies have shown that 
VEGFs also play an important role in protecting the fetus 
and placenta, and suppression of plasma VEGF can lead 
to defects in the embryo and even miscarriage [7]. 
Intravitreal anti-vascular endothelial growth factor 
agents are thus unsuitable for use during pregnancy due 
to systemic side effects they may cause on the mother as 
well as potential increased risks of harming the fetus, 
spontaneous miscarriage and preeclampsia [8, 9]. 
Even though it not yet known whether anti-VEGFs can 
enter the placenta, it has been shown that these drugs 
enter the systemic circulation shortly after intravitreal 
injection [10]. Thus, it would be reasonable to conjecture 
that anti-VEGFs negatively impact fetal health by 
entering the systemic circulation and suppressing plasma 
VEGF levels. Of anti-VEGFs that are currently in use, 
Ranibizumab clears the fastest from the systemic 
circulation and has the lowest impact on plasma VEGF 
levels. Indeed, it was shown that a single IVR injection 
significantly decreases plasma VEGF levels for just one 
day. In contrast, a significant decrease in plasma VEGF 
levels have been observed for at least one month 
following a single dose of Bevacizumab [11, 12]. There 
have been three cases reported in the literature of 
miscarriage following treatment with Bevacizumab and 
one of these cases had other risk factors for miscarriage. 
Two of the cases were reported by Petrou et al. aged 29 
and 25 who received intravitreal injection during the 4th 
and 3rd weeks of pregnancy, respectively. The first case 
had diabetic macular edema known as type 1 diabetes 
subject, while the second was diagnosed with choroidal 
neovascularization related to myopia. Miscarriage 
occurred 7 and 10 days after intravitreal Bevacizumab 
injections, respectively [13]. The third case was a 41-
year-old woman with a miscarriage 7 weeks after a 
Bevacizumab injection [14]. However, the patient in this 
report had other risk factors for miscarriage, such as old 
age. Furthermore, Sullivan et al. reported a patient who 
developed preeclampsia after 3 doses of intravitreal 
Bevacizumab, the last of which occurred during 
pregnancy [6]. Other case reports in the literature 
describe women who experienced no adverse events 
during pregnancy despite Bevacizumab injections at 
similarly early gestational time points [2]. 
To the best of our knowledge, this is considered as the 
first report in the literature of a loss of pregnancy after 
an IVR injection. In this case, the injection was made 
within the first 5 weeks of pregnancy. In all of the 
previously described cases of miscarriage following IVA 
injection, miscarriage occurred 7–10 days after injection. 
Similarly, miscarriage occurred 6 days after injection in 
the present case.  
No study has reported any cases of newborn 
teratogenicity due to treatment with IVAs. However, one 
case has been published describing premature birth 
following IVA treatment, although this patient had other 
risk factors [2]. The timing of IVA treatment during 
pregnancy is crucial. If IVA treatment is deemed 
necessary during pregnancy, its benefits and possible 
harms should be explained to patient in detail. Whenever 
possible treatment should be postponed until 
organogenesis is complete at approximately 8-weeks 
after post-fertilization.  
The risk of spontaneous miscarriage in clinically defined 
pregnant women has been reported to range from 
approximately 11% to 16%, and the cases of miscarriage 
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following IVA treatment in the literature may thus be 
unrelated to exposure to IVAs [15]. However, the 
common factors described in many of the cases in the 
literature require attention. Specifically in many of the 
reported cases including the present case, without any 
other risk factors, IVR injection within the first 5 weeks of 
the pregnancy caused miscarriage 6 to 10 days after 
injection. 
CONCLUSIONS 
Intravitreal Ranibizumab may cause miscarriage, 
especially at first trimester. However, Ranibizumab is the 
least risky one among other anti-VEGF agents, because 
Ranibizumab clears the fastest from the systemic 
circulation and has the lowest impact on plasma VEGF 
levels. 
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